Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

Summary

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Amgen Inc
ArQule Inc
Astellas Pharma Inc
AstraZeneca Plc
Blueprint Medicines Corp
Bristol-Myers Squibb Company
Eisai Co Ltd
Eli Lilly and Company
Genosco Inc
H3 Biomedicine Inc
Incyte Corp
Ionis Pharmaceuticals Inc
Johnson & Johnson
NGM Biopharmaceuticals Inc
Novartis AG
Principia Biopharma Inc
Tasly Pharmaceutical Group Co Ltd
Vichem Chemie Research Ltd
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ARQ-087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-709 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-9931 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golvatinib tartrate + lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-62079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-463588 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSLB-1344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 05, 2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting
Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting
May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting
May 17, 2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting
Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Apr 22, 2017: NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Apr 05, 2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting
Apr 05, 2017: NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017
Mar 28, 2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting
Mar 28, 2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma
Mar 27, 2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences
Mar 23, 2017: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug
Mar 09, 2017: H3 Biomedicine to Present on H3B-6527 at 2017 American Association of Cancer Research Annual Meeting
Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
Jan 04, 2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer